You Too Can Treat Hepatitis C

Leslie Enzian, MD  enzian@uw.edu

Pioneer Square Clinic
Seattle, Washington
National Health Care for the Homeless Annual Conference 2017
Disclosures

None
Objectives

• The Case for Primary Care Rx of HCV
• Review Epidemiology, Staging and Preparation for Treatment
• Legal requirements for treatment, resources of telemedicine specialty consultation
• Clinic treatment model
• Resources for treatment recommendations
Epidemiology

- ~3.5 million living with HCV in U.S.
  - 38% linked to care, 11% treated
- 33,900 New Cases/yr
- 2010 to 2015: 3-Fold increase
- 10-20 times in some homeless populations
- 12-35% of those incarcerated
- LA Study 534 homeless patients: 26.7% HCV-positive (Ab), 46% unaware, 72.6% never received counseling about HCV Gelberg, 2012
HCV Transmission

Injecting drug use, 60 percent
Sexual, 15 percent
Transfusion, 10 percent (before screening)
Unknown, 10 percent
Other*, 5 percent

* Nosocomial; health-care work; perinatal.
Centers for Disease Control and Prevention.

UpToDate 2019
## AASLD/IDSA HCV Testing Recommendations

One-time HCV testing is recommended for persons born between 1945 and 1965, without prior ascertainment of risk (and regardless of country of birth)

*Rating: Class 1, Level B*

Other persons should be screened for risk factors for HCV infection, and one-time testing should be performed for all persons with behaviors, exposures, and conditions associated with an increase risk of HCV infection.

### 1. Risk behaviors

- Injection-drug use (current or ever, including those who injected once)
- Intranasal illicit drug use

### 2. Risk exposures

- Long-term hemodialysis (ever)
- Getting a tattoo in an unregulated setting
- Healthcare, emergency medical, and public safety workers after needlesticks, sharps, or mucosal exposures to HCV-infected blood
- Children born to HCV-infected women
- Prior recipients of transfusions or organ transplants, including persons who:
  - were notified they received blood from a donor who later tested positive for HCV infection
  - received transfusion of blood or blood components, or underwent organ transplant before July 1992
  - received clotting factor concentrates produced before 1987
- Persons who were ever incarcerated

### 3. Other

- HIV infection
- Unexplained chronic liver disease and chronic hepatitis including elevated alanine aminotransferase levels
- Solid organ donors (deceased and living)

*Rating: Class 1, Level B*
Sexual Activity Counseling

• Risk of heterosexual transmission low. Those in long-term monogamous relationships do not need to alter their sexual practices

• Risk may be substantial for sexual practices that may result in bleeding/mucosal damage — use condoms and avoid rough sex.
Greater Progression Risk:
Male, HIV, HBV, Diabetes, Obesity, Hepatic Steatosis, low Vitamin D, EtOH, daily MJ use, high cholesterol diet.
Impact of Hepatitis C

• Leading Cause of:
  – End Stage Liver Disease
  – Hepatocellular Carcinoma
  – Liver Transplantation

• Survival Impact
  – 8000-13,000 deaths/year

• Extrahepatic Manifestations
  – Potentially life-threatening, prevented by Rx
  – Renal, hematologic, autoimmune, derm, DM

• QOL, Fatigue, Cognition, Stigma
Mortality Rates 1999-2008
New Era of Treatment: Direct-Acting Antivirals (DAA)

- Shorter duration: 8-12 weeks
- Fewer side effects: Nausea, HA, fatigue
- Higher cure rates
- Guidelines: Rx recommended in all patients
  - exception life expectancy <12 months due to non-related conditions
  - Short life-expectancy due to liver disease—refer to a specialist
Five-year mortality rates (95% confidence interval) for sustained virologic response (SVR) vs non-SVR groups for each cohort. (Simmons, 2015)
Childs A Rx impact on cirrhosis

• IFN: SVR assoc w/ decreasing Portal Pressures, prevention of varices, decreased hepatic decompensation, and HCC.

• Fibrosis regression does not happen in all patients after SVR even in non-cirrhotics (7-12%)

• If regression occurs it takes a long time. Several studies have shown fibrosis regression at a median of >5 years. In a study by Lens et al, clinical significant portal HTN (HVPG> 6mm/Hg) persisted 6 months post treatment in 86% of patients in spite of good>10mm/Hg reduction

EchoHCV, 2017
Childs Class B/C Rx impact

• Limited data from IFN trials
  In registration trials and expanded access trials an
  initial improvement in 6-month MELD
  but 15-month deterioration

• 1 study, DAA Rx w/ SVR associated w/ lower portal
  pressures
  – long term benefit unknown at this point
    \( (Afdhal \ et \ al, \ 2016) \)

\textit{echo HCV, 2017}
Rx Impact on Development of HCC

• IFN: clear benefit of 75% reduced HCC risk w/ SVR
• Would suspect this to be higher with DAA since more people getting SVR, data not definitive
• This topic remains controversial. Therefore all cirrhotic patients should be routinely screened for HCC
Why should PCP Treat HCV?

- Limited access
- Pre-established therapeutic relationships
  - BHCHP Survey: majority of pts most comfortable with PCP Rx
- Access to other care needs
- Skills in engaging disenfranchised patients
- Uncomplicated HCV benefits from treatment
- PCP Rx outcomes with telemedicine consultation:
  - ~ 2X increase in HCV PCR + pts starting Rx (Mitruka, 2014)
  - Equally safe and effective in achieving cure (Arora, 2010)
- ASCEND Trial: 3-Hour training PCPs vs Providers as safe/effective (Kattakuzhy, 2017)
Barriers to Treatment by PCP

- Patient fear of side effects
- No perceived need for treatment
- State Legal restrictions
- Lack of expertise
- Rapid scientific evolution of care
- Lack of Rx coverage (Pharm assistance options)
- Lack of support staff to process approvals
- High Volume, requires frequent follow-up
- Pioneer Square Process
Judge orders Washington Medicaid to provide lifesaving hepatitis C drugs for all

A federal judge has ordered Washington’s Medicaid program to end a 2015 policy that limited expensive drugs that can cure hepatitis C infections to patients with the most severe liver disease.

The injunction was a response to a class-action lawsuit filed in February on behalf of two clients of Apple Health — and nearly 28,000 other Medicaid enrollees with hepatitis C.
WA Legal Restrictions on Rx:

• Prescriber is:
  – A specialist* in one of the following areas:
    • Gastroenterologist, Hepatologist, HIV, Infectious disease; OR

• Prescriber is participating and consulting with Project ECHO or one of the specialists listed above (requires consultation note or documentation of phone call)

• Exceptions possible if training in HCV care or ready access to specialists
Telemedicine: ECHO HCV

• Specialty support for PCPs to increase access to best practice management for complex diagnoses
• Set-up/cost--minimal
• ECHO process—who participates, frequency, structure
• ECHO resources
• Option for future independent treatment
Treatment Selection

• Consistency in follow-up
• Ability to adhere to regimen
• Motivation for treatment
• EtOH use disorders
• Drug use disorders
• Who requires specialty referral?
Rx Outcomes and Alcohol

% SVR

- No Cirrhosis
- Cirrhosis

Degree of Alcohol Use
- Abstinent
- Low-Level
- Unhealthy

Adapted from Drug And Alcohol Dependence, Vol 169, 2016
Treatment of PWID

- Rx often withheld due to perceived
  - Adherence, cost, resistance, reinfection
- Significant public health impact
- High response rates
- Low likelihood of reinfection even with continued use
Treatment of PWID

• Rx integration in 3 OAT programs: PREVAIL *(Annals, 2019)*
  – Non-blinded RCT: DOT vs Group Therapy vs self-admin,
  – Assessed adherence, Rx completion, SVR
  – High SVR all groups, even with ongoing drug use
  – Drug use did not affect adherence or SVR
  – Rx failures deaths with (-) VL, stopped Rx, lost f/u

• HERO Study: Patient Centered Treatment
  – DOT vs Patient Navigators
  – Rx initiation, adherence, Rx completion, resistance, reinfection
Specialty Care Considerations

- Childs Class B or C cirrhosis
- Hepatic nodules concerning for HCC
- DAA Treatment failure
- HIV coinfection
- Significant extrahepatic complications
- Renal Failure
- HBV DNA (+)
- If isolated Hep B Core Ab (+), monitor AST, ALT monthly during Rx—risk of reactivation
Preparation for Treatment

- Confirm chronicity of infection at 6 months
- Counsel on infection control
- Screen/Vaccinate for Hep A/B
- Identify Genotype, check baseline labs
- Treatment Naïve or Experienced
- Assess Staging (Review past biopsy, US or CT)
- Imaging & Scoring if advanced fibrosis
- ECHO or specialty consultation
- Refer appropriate patients for specialty care
Relevance of Staging

• Informs choice or duration of Rx regimen
• May determine coverage
• Inform need for HCC screening
• Inform need for varices screening
• Inform monitoring or Rx for decompensated cirrhosis
Fibrosis Stage

Staging according to Metavir Score

F1: Portal fibrosis
F2: Portal fibrosis with few septa
F3: Septal fibrosis
F4: Cirrhosis

www.pathologyoutlines.com
Sampling Error of Liver Biopsy

Fibrosis area: 65%

Fibrosis area: 15%

Courtesy of M. Pinzani, Florence
## Liver Biopsy Size in 355 Samples: The Smaller the Piece the Milder the Disease

<table>
<thead>
<tr>
<th>Length of specimen</th>
<th>&gt; 3 cm</th>
<th>1.5 cm</th>
<th>1 cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. Portal Tracts</td>
<td>complete</td>
<td>22.4 ± 4.9</td>
<td>10.3 ± 2.2</td>
</tr>
<tr>
<td>Grade</td>
<td>Mild</td>
<td>49.7%</td>
<td>60.2%</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>38.5%</td>
<td>39.1%</td>
</tr>
<tr>
<td></td>
<td>Severe</td>
<td>11.8%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Stage</td>
<td>Mild (F0-1)</td>
<td>59%</td>
<td>68.3%</td>
</tr>
<tr>
<td></td>
<td>Moderate (F2)</td>
<td>29.8%</td>
<td>24.2%</td>
</tr>
<tr>
<td></td>
<td>Severe (F3-4)</td>
<td>11.2%</td>
<td>7.4%</td>
</tr>
</tbody>
</table>

Colloredo, J Hep, 2003
Liver Biopsy Optimal:

Optimal: 16G cutting needle, 3 passes, 3 X 1 cm (2 cm acceptable), 11 portal tracts

Rockey DC et al. Hepatology 2009;1017-44.

A. 2.7 cm, 2 passes 16G cutting needle
B. 4.8 cm, 3 passes 18G cutting needle
C. 1.1 cm, 16G suction needle
D. .5 cm, 18G needle
E. 1.5 cm, 20G needle
Non-invasive Fibrosis Staging

• Indirect laboratory markers
  – APRI, Fib-4
  – Good at excluding/confirming fibrosis
  – Indeterminate in mid-range

• Indirect biochemical markers
  – FibroTest: Age, gender, 6 serum markers

• Imaging: US, CT, elastography, fibroscan

• Ideally off EtOH X 3 months prior to staging
Hepatic Elastography

Sensitivity of 84 - 100% and Specificity of 91 - 96%.
Staging Low Down

- 2 non-invasive tests:
  - Fibroscan (best) + APRI
  - Fibroscan + FibroTest
  - FibroTest + APRI

- US if suggestion of cirrhosis

- Discordant results that would affect Rx decision
  - Low (F0-2) vs High (F3-4)
    - Consider Fibroscan (if not done) or Biopsy

- Staging those not getting Rx can guide screening
Hepatitis C Virus

- Single stranded, RNA virus
- Exists as seven genotypes
  - 1a and b, 2, 3, 4, 5, 6
- Transmitted through blood and sexual contact
- GT 3 Resistant Associated Variants impacts management for cirrhotics
  - Y90 mutation
  - Order RAV testing
Direct Acting Antivirals

- **NS5B Inhibitors (RNA Polymerase Inhibitors)** - Sofosbuvir, Dasabuvir

- **NS5A Inhibitors** - Ledipasvir, Ombitasvir, Elbasvir, Velpatasvir, Pibrentasvir

- **NS3A/4A(Protease Inhibitors)** - Simeprevir, Paritaprevir, Grazoprevir, Glecaprevir, Voxilaprevir
Direct Acting Antiviral Products

• Harvoni: Ledipasvir/Sofosbuvir
  – 1 tablet once daily

• Mavyret: Glecaprevir/Pibrentasvir
  – 3 tablets once daily, 8-12 weeks
  – Preferred all GT in WA

• Epclusa: Sofosbuvir/Velpatasvir, 12 weeks

• Zepetier: Elbasvir/Grazoprevir

• Vosevi: Sofosbuvir/Velpatasvir/Voxilaprevir
Drug Interactions

• PPI and Harvoni
• Statin and Mavyret
• HCV Drug Interactions: http://files.ctctcdn.com/f941a670501/a16351c7-423e-4a2a-8c36-59ae9901976c.pdf
Post-treatment Management

• SVR monitoring
  – **SVR 12** = 12 weeks post-treatment for F0-F3
  – **SVR 12, 24** for F4 or HIV Coinfection

• HCC screening US every 6 mo: For F3 and F4

• EGD screening for varices: For F4
  – No EGD if plt > 150K & Liver Stiffness < 20 kPa (*Garcia-Tsao, 2017*)

• Continued HCV screening for those at risk

• Counseling reinfection possible
Clinical Pearls

• Do not switch insurance during Rx
• Bring meds to the hospital, jail or rehab
• No replacements for lost medications or very difficult to get a lost medication override
• Contraception
• Address HCV status & treatment for partners
Random Fun Facts

- Low viral load (< 6 million) can indicate mild viral activity or advanced fibrosis with few hepatocytes for HCV to replicate in.
- As fibrosis progresses the ALT > AST can “flip” as hepatocytes die (AST has other sources).
- Treatment does not confer immunity, reinfection can occur after spontaneous clearance or SVR—continue screening.
- Chronic HCV can spontaneously clear.
- Isolated HBV Core Ab—no vaccination indicated.
- Email us with any questions.
Hepatitis C Resources

• AASLD Guideline hcvguidelines.org
• Hepatitis C Online hepatitisc.uw.edu
  – Calculators for APRI, Childs Class, MELD
• EASL Guidelines easl.eu/research/our-contributions/clinical-practice-guidelines
• ECHO Project: www.echo.unm.edu
• hcvadvisor.com (EASL web-based Rx recommendations)
• Web-based/Smartphone resources/consultation: hepcure.org
Resources

• HCV Drug Interactions: http://files.ctctcdn.com/f941a670501/a16351c7-423e-4a2a-8c36-59ae9901976c.pdf

• Patient Access Network Foundation(PAN) www.panfoundation.org

• Rx Schedule Date Calculator: Timeanddate.com

Acknowledgements

• Pioneer Square Clinic Staff
• Project ECHO
• 7MB Pharmacists and Technicians
Appendix Topics

• HCV Screening
• Transmission Counseling
• Accuracy of indirect markers for staging
• Extrahepatic Manifestations
• Rx in PWID—Guideline information
• Post-Rx progression of liver disease
• Random Fun Facts
## Overview of Hepatitis C

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Geographic area with highest prevalence</th>
</tr>
</thead>
</table>
| 1        | 70 – 75% of all HCV infections in USA  
          | North America                          
          | Asia/Australia/Europe/South America    |
| 2        | 13 – 15% of all HCV infections in USA  
          | South America & West Africa            |
| 3        | 10% of all HCV infections in USA        
          | India and parts of South East Asia     |
| 4        | Egypt, North Africa, sub-Saharan Africa |
| 5        | South Africa and some part of Europe    |
| 6        | China, Korea, Taiwan, Southeast Asia    |
Transmission Counseling

- Reinfection possible
- Avoid the new use of injection drugs and stop current use of injection drugs
- Reduce the frequency of injecting
- Use new, sterile needles, syringes, cotton, water, cookers each time you inject
- Do not share or reuse needles or syringes
- Safely dispose of needles and syringes
- Do not reuse or share other injection materials (cookers, cottons, water, drug)
- Receive substance-use treatment and support for safe injection practices
Pre-treatment Testing

• Genotype, complete metabolic panel, CBC, INR, Viral load
  – Within past 3 months
• HIV testing within the past year
• HAV and HBV serologies
\[
\text{APRI} = \left( \frac{\text{AST Level}}{\text{AST (Upper Limit of Normal)}} \right) \times \frac{\text{Platelet Count (10}^9/\text{L})}{100}
\]

Figure 3 - Aspartate Aminotransferase-to-Platelet-Ratio Index (APRI)
APRI

- Cut-off $\leq 0.7$: Sensitivity 77% for ruling out $\geq$ F2 stages
- Cut-off $\geq 2.0$: Specificity 91% (sens 46%), good for ruling in F3-F4, $\geq 1.5$ threshold used by Medicaid
- Intermediate range (0.7-1.4) results have poor reliability
- Use APRI in combo with 2nd non-invasive test
Figure 4 - Fib4
The Fib4 represents an easy-to-use test for predicting severe hepatic fibrosis or cirrhosis (Vallet-Pichard, 2007)

\[
FIB-4 = \frac{\text{Age (years)} \times \text{AST (U/L)}}{\text{Platelet Count (10}^9/\text{L}) \times \sqrt[{}]{\text{ALT (U/L)}}}
\]
FIB-4

• < 1.45: F0-F2 (spec. 80%, sens 74%, NPV 90%)
• > 3.25: F3-F4 (specificity 97%)
• Intermediate ranges not reliable
• Overall accuracy of 86% in avoiding liver biopsy (70% cohort in cut-off ranges)
• Use in combo with 2\textsuperscript{nd} non-invasive test
FibroTest

- Predicts histology based on 6 biochemical tests, age and gender
- Haptoglobin, α2-macroglobulin, apolipoprotein A1, GGT, bilirubin, ALT
- Costs ~ $250
- NPV F0-F1 = 85%
- PPV F3-F4 = 76%
- Intermediate values not reliable,
- Cr > 1.5: if Fibrosure elevated, may not be accurate
<table>
<thead>
<tr>
<th>Hepatitis C-Related Extrahepatic Manifestations</th>
<th>Potential HCV-Related Syndrome</th>
</tr>
</thead>
</table>
| Hypertension                                  | Membranoproliferative glomerulonephritis  
Nephropathy                                   |
|                                               | Cryoglobulinemia                    |
| Skin disease                                  | Lichen planus                       |
|                                               | Porphyria cutanea tarda              |
|                                               | Leukocytoclastic vasculitis          |
|                                               | Cryoglobulinemia vasculitis          |
| Purpura                                       | Cryoglobulinemic vasculitis          |
|                                               | Leukocytoclastic vasculitis          |
| Distal neuropathic pain                       | Membranoproliferative glomerulonephritis without cryoglobulin |
|                                               | Cryoglobulinemia-Membranoproliferative glomerulonephritis |
| Renal insufficiency Hematuria                 | Membranoproliferative glomerulonephritis without cryoglobulin |
|                                               | Cryoglobulinemia-Membranoproliferative glomerulonephritis |
| Lymphadenopathy                               | Lymphoproliferative disorder         |
| Fever                                         | Cryoglobulinemia                     |
|                                               | Cryoglobulinemic vasculitis          |
|                                               | Lymphoproliferative disorder         |
| Arthralgia, weakness                          | Cryoglobulinemia                     |
|                                               | Lymphoma                             |
|                                               | Cryoglobulinemic vasculitis          |
Ideally, treatment of HCV-infected persons who inject drugs should be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population. Regardless of the treatment setting, recent and active IDU should not be seen as an absolute contraindication to HCV therapy. There is strong evidence from various settings in which persons who inject drugs have demonstrated adherence to treatment and low rates of reinfection, countering arguments that have been commonly used to limit access to this patient population (Aspinall, 2013); (Hellard, 2014); (Grebely, 2011). Indeed, combining HCV treatment with needle exchange and opioid agonist therapy programs in this population with a high prevalence of HCV infection has shown great value in decreasing the burden of HCV disease. Elegant modeling studies illustrate the high return on the modest investment of addressing this often-ignored segment of the HCV-infected population (Martin, 2013b). These conclusions were drawn before the introduction of the latest DAA regimens. Conversely, there are no data to support the utility of pretreatment screening for illicit drug or alcohol use in identifying a population more likely to successfully complete HCV therapy. These requirements should be abandoned, because they create barriers to treatment, add unnecessary cost and effort, and potentially exclude populations that are likely to obtain substantial benefit from therapy. Scale up of HCV treatment in persons who inject drugs is necessary to positively impact the HCV epidemic in the United States and globally.
Contacts:

- Leslie Enzian, MD  enzian@uw.edu
- Mary Kelly, Pharm D, CDE  mskelly@uw.edu